Jay Olson
Stock Analyst at Oppenheimer
(4.30)
# 349
Out of 5,182 analysts
250
Total ratings
45.54%
Success rate
19.77%
Average return
Main Sectors:
Stocks Rated by Jay Olson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIIB Biogen | Maintains: Outperform | $250 → $275 | $172.97 | +58.99% | 27 | Apr 1, 2026 | |
| PASG Passage Bio | Initiates: Outperform | $30 | $9.89 | +203.34% | 1 | Mar 31, 2026 | |
| BCYC Bicycle Therapeutics | Maintains: Outperform | $44 → $36 | $4.94 | +628.74% | 5 | Mar 18, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $540 → $600 | $436.27 | +37.53% | 2 | Mar 10, 2026 | |
| BIOA BioAge Labs | Initiates: Outperform | $60 | $16.19 | +270.60% | 1 | Feb 25, 2026 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Perform | $21 → $23 | $21.74 | +5.80% | 16 | Feb 6, 2026 | |
| RVMD Revolution Medicines | Maintains: Outperform | $75 → $150 | $96.43 | +55.55% | 10 | Jan 27, 2026 | |
| CHRS Coherus Oncology | Initiates: Outperform | $10 | $1.68 | +495.24% | 1 | Jan 22, 2026 | |
| PRAX Praxis Precision Medicines | Maintains: Outperform | $250 → $750 | $316.14 | +137.24% | 3 | Dec 15, 2025 | |
| TERN Terns Pharmaceuticals | Maintains: Outperform | $28 → $58 | $52.63 | +10.20% | 4 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $600 → $650 | $519.61 | +25.09% | 12 | Nov 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $2.16 | +131.48% | 1 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $84 → $90 | $75.17 | +19.73% | 4 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $21 → $30 | $5.52 | +443.48% | 3 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $14 | $3.64 | +284.62% | 1 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $10.50 | - | 15 | May 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $65 | $2.90 | +2,141.38% | 1 | May 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $65 | $0.80 | +8,001.71% | 5 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $13 | $1.06 | +1,126.42% | 3 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $90 | $77.50 | +16.13% | 6 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $42 | $19.23 | +118.41% | 4 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $41 → $33 | $44.27 | -25.46% | 6 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $40 | $13.49 | +196.52% | 9 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $20 | $5.05 | +296.04% | 2 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $5.30 | +466.04% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $81 → $82 | $96.07 | -14.65% | 14 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $138 | $34.26 | +302.80% | 8 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $8 | $1.80 | +344.44% | 1 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $380 | $351.02 | +8.26% | 23 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $216 → $219 | $128.89 | +69.91% | 15 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $12 | $2.94 | +308.16% | 6 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 | $3.74 | +381.28% | 5 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $100 | $25.86 | +286.70% | 5 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $102 → $95 | $51.22 | +85.47% | 6 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $0.72 | +3,372.22% | 1 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 | $0.90 | +894.91% | 4 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,200 → $500 | $1.35 | +36,937.04% | 4 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $25 → $21 | $14.11 | +48.83% | 9 | Nov 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $7.29 | - | 2 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $84 | $17.85 | +370.59% | 1 | Mar 20, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $2.07 | - | 3 | Jul 11, 2017 |
Biogen
Apr 1, 2026
Maintains: Outperform
Price Target: $250 → $275
Current: $172.97
Upside: +58.99%
Passage Bio
Mar 31, 2026
Initiates: Outperform
Price Target: $30
Current: $9.89
Upside: +203.34%
Bicycle Therapeutics
Mar 18, 2026
Maintains: Outperform
Price Target: $44 → $36
Current: $4.94
Upside: +628.74%
Vertex Pharmaceuticals
Mar 10, 2026
Maintains: Outperform
Price Target: $540 → $600
Current: $436.27
Upside: +37.53%
BioAge Labs
Feb 25, 2026
Initiates: Outperform
Price Target: $60
Current: $16.19
Upside: +270.60%
ACADIA Pharmaceuticals
Feb 6, 2026
Maintains: Perform
Price Target: $21 → $23
Current: $21.74
Upside: +5.80%
Revolution Medicines
Jan 27, 2026
Maintains: Outperform
Price Target: $75 → $150
Current: $96.43
Upside: +55.55%
Coherus Oncology
Jan 22, 2026
Initiates: Outperform
Price Target: $10
Current: $1.68
Upside: +495.24%
Praxis Precision Medicines
Dec 15, 2025
Maintains: Outperform
Price Target: $250 → $750
Current: $316.14
Upside: +137.24%
Terns Pharmaceuticals
Dec 9, 2025
Maintains: Outperform
Price Target: $28 → $58
Current: $52.63
Upside: +10.20%
Nov 20, 2025
Maintains: Outperform
Price Target: $600 → $650
Current: $519.61
Upside: +25.09%
Oct 21, 2025
Initiates: Outperform
Price Target: $5
Current: $2.16
Upside: +131.48%
Oct 8, 2025
Maintains: Outperform
Price Target: $84 → $90
Current: $75.17
Upside: +19.73%
Sep 25, 2025
Maintains: Outperform
Price Target: $21 → $30
Current: $5.52
Upside: +443.48%
Jul 29, 2025
Initiates: Outperform
Price Target: $14
Current: $3.64
Upside: +284.62%
May 27, 2025
Downgrades: Perform
Price Target: n/a
Current: $10.50
Upside: -
May 21, 2025
Initiates: Outperform
Price Target: $65
Current: $2.90
Upside: +2,141.38%
May 15, 2025
Maintains: Outperform
Price Target: $80 → $65
Current: $0.80
Upside: +8,001.71%
May 14, 2025
Maintains: Outperform
Price Target: $15 → $13
Current: $1.06
Upside: +1,126.42%
Mar 14, 2025
Upgrades: Outperform
Price Target: $90
Current: $77.50
Upside: +16.13%
Mar 3, 2025
Maintains: Outperform
Price Target: $50 → $42
Current: $19.23
Upside: +118.41%
Jan 24, 2025
Downgrades: Perform
Price Target: $41 → $33
Current: $44.27
Upside: -25.46%
Jan 13, 2025
Maintains: Outperform
Price Target: $60 → $40
Current: $13.49
Upside: +196.52%
Dec 11, 2024
Maintains: Outperform
Price Target: $80 → $20
Current: $5.05
Upside: +296.04%
Dec 6, 2024
Initiates: Outperform
Price Target: $30
Current: $5.30
Upside: +466.04%
Oct 30, 2024
Maintains: Outperform
Price Target: $81 → $82
Current: $96.07
Upside: -14.65%
Sep 25, 2024
Reiterates: Outperform
Price Target: $138
Current: $34.26
Upside: +302.80%
Aug 14, 2024
Assumes: Outperform
Price Target: $8
Current: $1.80
Upside: +344.44%
Aug 7, 2024
Maintains: Outperform
Price Target: $380
Current: $351.02
Upside: +8.26%
Aug 2, 2024
Maintains: Outperform
Price Target: $216 → $219
Current: $128.89
Upside: +69.91%
Jun 18, 2024
Maintains: Perform
Price Target: $12
Current: $2.94
Upside: +308.16%
May 15, 2024
Maintains: Outperform
Price Target: $18
Current: $3.74
Upside: +381.28%
May 15, 2024
Maintains: Outperform
Price Target: $100
Current: $25.86
Upside: +286.70%
May 10, 2024
Maintains: Outperform
Price Target: $102 → $95
Current: $51.22
Upside: +85.47%
Apr 12, 2024
Initiates: Outperform
Price Target: $25
Current: $0.72
Upside: +3,372.22%
Mar 27, 2024
Maintains: Outperform
Price Target: $9
Current: $0.90
Upside: +894.91%
Nov 30, 2023
Maintains: Outperform
Price Target: $1,200 → $500
Current: $1.35
Upside: +36,937.04%
Nov 22, 2023
Maintains: Perform
Price Target: $25 → $21
Current: $14.11
Upside: +48.83%
Oct 13, 2022
Downgrades: Perform
Price Target: n/a
Current: $7.29
Upside: -
Mar 20, 2018
Maintains: Outperform
Price Target: $70 → $84
Current: $17.85
Upside: +370.59%
Jul 11, 2017
Upgrades: Outperform
Price Target: n/a
Current: $2.07
Upside: -